{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T05:35:27Z","timestamp":1793079327142,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00428-026-04401-9","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:48:29Z","timestamp":1768996109000},"page":"953-962","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinicopathologic and molecular characterization of uterine and ovarian mixed yolk sac tumor and carcinoma\/carcinosarcoma: implications for somatic derivation and therapeutics"],"prefix":"10.1007","volume":"489","author":[{"given":"Jian","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7309-1116","authenticated-orcid":false,"given":"Bingjian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"4401_CR1","unstructured":"Cao D, Vang R (202) Yolk sac tumour. In: WHO Classification of Tumours Board (ed) Female genital tumours: WHO classification of tumours, 5th ed. IARC, Lyon, pp 125\u2013128"},{"key":"4401_CR2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/PGP.0000000000000078","volume":"33","author":"AA Roma","year":"2014","unstructured":"Roma AA, Przybycin CG (2014) Yolk sac tumor in postmenopausal patients: pure or associated with adenocarcinoma, a rare phenomenon. Int J Gynecol Pathol 33:477\u2013482. https:\/\/doi.org\/10.1097\/PGP.0000000000000078","journal-title":"Int J Gynecol Pathol"},{"key":"4401_CR3","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1038\/s41379-019-0341-6","volume":"32","author":"O Fadare","year":"2019","unstructured":"Fadare O, Shaker N, Alghamdi A, Ganesan R, Hanley KZ, Hoang LN, Hecht JL, Ip PP, Shaker N, Roma AA, Parkash V, Abubakr H (2019) Endometrial tumors with yolk sac tumor-like morphologic patterns or immunophenotypes: an expanded appraisal. Mod Pathol 32:1847\u20131860. https:\/\/doi.org\/10.1038\/s41379-019-0341-6","journal-title":"Mod Pathol"},{"key":"4401_CR4","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/his.13021","volume":"69","author":"T McNamee","year":"2016","unstructured":"McNamee T, Damato S, McCluggage WG (2016) Yolk sac tumours of the female genital tract in older adults derive commonly from somatic epithelial neoplasms: somatically derived yolk sac tumours. Histopathology 69:739\u2013751. https:\/\/doi.org\/10.1111\/his.13021","journal-title":"Histopathology"},{"key":"4401_CR5","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/his.14188","volume":"77","author":"AM Acosta","year":"2020","unstructured":"Acosta AM, Sholl LM, Cin PD, Howitt BE, Otis CN, Nucci MR (2020) Malignant tumours of the uterus and ovaries with Mullerian and germ cell or trophoblastic components have a somatic origin and are characterised by genomic instability. Histopathology 77:788\u2013797. https:\/\/doi.org\/10.1111\/his.14188","journal-title":"Histopathology"},{"key":"4401_CR6","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1038\/s41379-020-0548-6","volume":"33","author":"SL Skala","year":"2020","unstructured":"Skala SL, Liu CJ, Udager AM, Sciallis AP (2020) Molecular characterization of uterine and ovarian tumors with mixed epithelial and germ cell features confirms frequent somatic derivation. Mod Pathol 33:1989\u20132000. https:\/\/doi.org\/10.1038\/s41379-020-0548-6","journal-title":"Mod Pathol"},{"key":"4401_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/PGP.0000000000000889","volume":"42","author":"GC Halling","year":"2023","unstructured":"Halling GC, Udager AM, Skala SL (2023) Endometrial, ovarian, and peritoneal involvement by endometrioid carcinoma, yolk sac tumor, and endometriosis: molecular evidence for a shared precursor. Int J Gynecol Pathol 42:247\u2013253. https:\/\/doi.org\/10.1097\/PGP.0000000000000889","journal-title":"Int J Gynecol Pathol"},{"key":"4401_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.humpath.2022.08.006","volume":"136","author":"SK Mohanty","year":"2023","unstructured":"Mohanty SK, Lobo A, Cheng L (2023) The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges. Hum Pathol 136:123\u2013143. https:\/\/doi.org\/10.1016\/j.humpath.2022.08.006","journal-title":"Hum Pathol"},{"key":"4401_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ygyno.2018.08.013","volume":"151","author":"E Van Nieuwenhuysen","year":"2028","unstructured":"Van Nieuwenhuysen E, Busschaert P, Neven P, Han SN, Moerman P, Liontos M, Papaspirou M, Kupryjanczyk J, Hogdall C, Hogdall E, Oaknin A, Garcia A, Mahner S, Trillsch F, Cibula D, Heitz F, Concin N, Speiser P, Salvesen H, Sehouli J, Lambrechts D, Vergote I (2028) The genetic landscape of 87 ovarian germcell tumors. Gynecol Oncol 151:61\u201368. https:\/\/doi.org\/10.1016\/j.ygyno.2018.08.013","journal-title":"Gynecol Oncol"},{"key":"4401_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/PGP.0000000000000711","volume":"40","author":"N Buza","year":"2021","unstructured":"Buza N (2021) HER2 testing and reporting in endometrial serous carcinoma: practical recommendations for HER2 immunohistochemistry and fluorescent in situ hybridization: proceedings of the ISGyP companion society session at the 2020 USCAP annual meeting. Int J Gynecol Pathol 40:17\u201323. https:\/\/doi.org\/10.1097\/PGP.0000000000000711","journal-title":"Int J Gynecol Pathol"},{"key":"4401_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002223","volume":"9","author":"X Huang","year":"2021","unstructured":"Huang X, He M, Peng H, Tong C, Liu Z, Zhang X, Shao Y, Zhu D, Zhang J, Yin JC, Yang F, Lan C (2021) Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial. J Immunother Cancer 9:e002223. https:\/\/doi.org\/10.1136\/jitc-2020-002223","journal-title":"J Immunother Cancer"},{"key":"4401_CR12","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/PAS.0000000000002230","volume":"48","author":"AM Mills","year":"2024","unstructured":"Mills AM, Jenkins TM, Dibbern ME, Atkins KA, Ring KL (2024) Yolk sac differentiation in endometrial carcinoma: incidence and clinicopathologic features of somatically derived yolk sac tumors versus carcinomas with nonspecificimmunoexpression of yolk sac markers. Am J Surg Pathol 48:790\u2013802. https:\/\/doi.org\/10.1097\/PAS.0000000000002230","journal-title":"Am J Surg Pathol"},{"key":"4401_CR13","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1097\/00000478-199609000-00003","volume":"20","author":"FF Nogales","year":"1996","unstructured":"Nogales FF, Bergeron C, Carvia RE, Alvaro T, Fulwood HR (1996) Ovarian endometrioid tumors with yolk sac tumor component, an unusual form of ovarian neoplasm. Analysis of six cases. Am J Surg Pathol 20:1056\u20131066. https:\/\/doi.org\/10.1097\/00000478-199609000-00003","journal-title":"Am J Surg Pathol"},{"key":"4401_CR14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1146\/annurev-pathol-020117-043609","volume":"14","author":"DW Bell","year":"2019","unstructured":"Bell DW, Ellenson LH (2019) Molecular genetics of endometrial carcinoma. Annu Rev Pathol 14:339\u2013367. https:\/\/doi.org\/10.1146\/annurev-pathol-020117-043609","journal-title":"Annu Rev Pathol"},{"key":"4401_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104603","volume":"208","author":"A Santoro","year":"2025","unstructured":"Santoro A, Angelico G, Travaglino A, Inzani F, Spadola S, Pettinato A, Mazzucchelli M, Bragantini E, Maccio L, Zannoni GF (2025) The multiple facets of ovarian high grade serous carcinoma: a review on morphological, immunohistochemical and molecular features. Crit Rev Oncol Hematol 208:104603. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104603","journal-title":"Crit Rev Oncol Hematol"},{"key":"4401_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23681-0","volume":"12","author":"X Zong","year":"2021","unstructured":"Zong X, Zhang Y, Peng X, Cao D, Yu M, Wang J, Li H, Guo X, Liang H, Yang J (202AD) Analysis of the genomic landscape of yolk sac tumors reveals mechanisms of evolution and chemoresistance. Nat Commun 12:3579. https:\/\/doi.org\/10.1038\/s41467-021-23681-0","journal-title":"Nat Commun"},{"key":"4401_CR17","doi-asserted-by":"publisher","first-page":"4516","DOI":"10.1158\/1078-0432.CCR-18-4278","volume":"25","author":"D Xing","year":"2019","unstructured":"Xing D, Zheng G, Pallavajjala A, Schoolmeester JK, Liu Y, Haley L, Hu Y, Liu L, Logan L, Lin Y, Pearce KE, Sattler CA, Tsai YC, Vang R, Hung CF, Wu TC, Ronnett BM (2019) Lineage-specific alterations in gynecologic neoplasms with choriocarcinomatous differentiation: implications for origin and therapeutics. Clin Cancer Res 25:4516\u20134529. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-4278","journal-title":"Clin Cancer Res"},{"key":"4401_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100049","volume":"36","author":"KD Doig","year":"2023","unstructured":"Doig KD, Fellowes AP, Fox SB (2023) Homologous recombination repair deficiency: an overview for pathologists. Mod Pathol 36:100049. https:\/\/doi.org\/10.1016\/j.modpat.2022.100049","journal-title":"Mod Pathol"},{"key":"4401_CR19","doi-asserted-by":"publisher","first-page":"e1526","DOI":"10.1002\/onco.13829","volume":"26","author":"M Toh","year":"2021","unstructured":"Toh M, Ngeow J (2021) Homologous recombination deficiency: cancer predispositions and treatment implications. Oncologist 26:e1526\u2013e1537. https:\/\/doi.org\/10.1002\/onco.13829","journal-title":"Oncologist"},{"key":"4401_CR20","doi-asserted-by":"publisher","unstructured":"Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673\u20131684. https:\/\/doi.org\/10.1056\/NEJMoa052122","DOI":"10.1056\/NEJMoa052122"},{"key":"4401_CR21","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, R\u00fcschoff J, Kang YK, ToGA Trial Investigators (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687\u2013697. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X","journal-title":"Lancet"},{"key":"4401_CR22","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","volume":"36","author":"AN Fader","year":"2018","unstructured":"Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O\u2019Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD (2018) Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu. J Clin Oncol 36:2044\u20132051. https:\/\/doi.org\/10.1200\/JCO.2017.76.5966","journal-title":"J Clin Oncol"},{"key":"4401_CR23","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","volume":"26","author":"AN Fader","year":"2020","unstructured":"Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O\u2019Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD (2020) Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res 26:3928\u20133935. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0953","journal-title":"Clin Cancer Res"},{"key":"4401_CR24","doi-asserted-by":"publisher","unstructured":"von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, W\u00fclfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr, KATHERINE Investigators (2019) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380:617\u2013628. https:\/\/doi.org\/10.1056\/NEJMoa1814017","DOI":"10.1056\/NEJMoa1814017"},{"key":"4401_CR25","doi-asserted-by":"publisher","unstructured":"Yuan R, Kay A, Berg WJ, Lebwohl D (2009) Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 45. https:\/\/doi.org\/10.1186\/1756-8722-2-45","DOI":"10.1186\/1756-8722-2-45"},{"key":"4401_CR26","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/annonc\/mdz116","volume":"30","author":"C Luchini","year":"2019","unstructured":"Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T, Miller R, Riaz N, Douillard JY, Andre F, Scarpa A (2019) ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol 30:1232\u20131243. https:\/\/doi.org\/10.1093\/annonc\/mdz116","journal-title":"Ann Oncol"},{"key":"4401_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/genes12121919","volume":"12","author":"TT Luong","year":"2021","unstructured":"Luong TT, Bernstein KA (2021) Role and regulation of the RECQL4 family during genomic integrity maintenance. Genes 12:1919. https:\/\/doi.org\/10.3390\/genes12121919","journal-title":"Genes"},{"key":"4401_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19041103","volume":"19","author":"EA Colombo","year":"2018","unstructured":"Colombo EA, Locatelli A, Cubells S\u00e1nchez L, Romeo S, Elcioglu NH, Maystadt I, Esteve Mart\u00ednez A, Sironi A, Fontana L, Finelli P, Gervasini C, Pecile V, Larizza L (2018) Rothmund-Thomson syndrome: insights from new patients on the genetic variability underpinning clinical presentation and cancer outcome. Int J Mol Sci 19:1103. https:\/\/doi.org\/10.3390\/ijms19041103","journal-title":"Int J Mol Sci"},{"key":"4401_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11082318","volume":"11","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Huang X, Wang L, Luo Y (2023) The expression characteristics and function of the RECQ family in pan-cancer. Biomedicines 11:2318. https:\/\/doi.org\/10.3390\/biomedicines11082318","journal-title":"Biomedicines"},{"key":"4401_CR30","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a004218","volume":"5","author":"JL Maciaszek","year":"2019","unstructured":"Maciaszek JL, Oak N, Chen W, Hamilton KV, McGee RB, Nuccio R, Mostafavi R, Hines-Dowell S, Harrison L, Taylor L, Gerhardt EL, Ouma A, Edmonson MN, Patel A, Nakitandwe J, Pappo AS, Azzato EM, Shurtleff SA, Ellison DW, Downing JR, Hudson MM, nRobison LL, Santana V, Newman S, Zhang J, Wang Z, Wu G, Nichols KE, Kesserwan CA (2019) Enrichment of heterozygous germline RECQL4 loss-of-function variants in pediatric osteosarcoma. Cold Spring Harb Mol Case Stud 5:a004218. https:\/\/doi.org\/10.1101\/mcs.a004218","journal-title":"Cold Spring Harb Mol Case Stud"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-026-04401-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-026-04401-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-026-04401-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T05:24:52Z","timestamp":1793078692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-026-04401-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4401"],"URL":"https:\/\/doi.org\/10.1007\/s00428-026-04401-9","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"16 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}